Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing *Enterobacterales* in the Antibiotic Resistance Laboratory Network, March 2019 to December 2020

Amelia Bhatnagar,a Sandra Boyd,a Sarah Sabour,a Janine Bodnar,b ElizabethNazarian,b Nadine Peinovich,b Christine Wagner,b Bradley Craft,c Paula Snippes Vagnone,c Justin Simpson,d Victoria N. Stone,d Michelle Therrien,d Allen Bateman,a Danielle Lower,a Jennifer Y. Huang,a Stephanie Gumbis,a David Lonsway,a Joseph D. Lutgring,a Maria Karlsson,a Allison C. Browna

aDivision of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
bWadsworth Center, New York State Department of Health, Albany, New York, USA
cMinnesota Department of Health, St. Paul, Minnesota, USA
dTennessee Department of Health, Nashville, Tennessee, USA
eWisconsin State Laboratory of Hygiene, Madison, Wisconsin, USA

Abstract Aztreonam-avibactam is a drug combination pending phase 3 clinical trials and is suggested for treatment of severe infections caused by metallo-beta-lactamase (MBL)-producing *Enterobacterales* by combining ceftazidime-avibactam and aztreonam. Beginning in 2019, four Antibiotic Resistance Laboratory Network regional laboratories offered aztreonam-avibactam susceptibility testing by broth microdilution. For 64 clinical isolates tested, the MIC₅₀ and MIC₉₀ values of aztreonam-avibactam were 0.5/4 µg/ml and 8/4 µg/ml, respectively. Aztreonam-avibactam displayed potent *in vitro* activity against the MBL-producing *Enterobacterales* tested.

Keywords *Enterobacterales*, MBL, antibiotic resistance, antimicrobial combinations, aztreonam-avibactam, beta-lactamases, carbapenemases, susceptibility testing

Metallo-beta-lactamase (MBL)-producing *Enterobacterales* are an emerging public health threat (1). Data collected between 2017 and 2019 by the Centers for Disease Control and Prevention’s (CDC) Antibiotic Resistance Laboratory Network (AR Lab Network) showed that MBL carbapenemase genes (*bla*IMP, *bla*NDM, and *bla*VIM) were present in 4.1% (1,743/42,423) of all carbapenem-resistant *Enterobacterales* (CRE) tested (2). These MBL genes, often located on mobile plasmids, commonly confer resistance to multiple beta-lactam agents, limiting the number of effective treatment options (3).

Recent case reports (4, 5) and *in vitro* studies (6–9) suggest that a novel drug combination, aztreonam-avibactam, may have efficacy against infections caused by MBL-producing *Enterobacterales*. Phase 3 clinical trials are pending, but the combination therapy of aztreonam-avibactam can currently be achieved by administering two Food and Drug Administration (FDA)-approved drugs, aztreonam and ceftazidime-avibactam. Additionally, the Infectious Diseases Society of America suggests this combination as a potential treatment option for infections caused by MBL-producing CRE (10).

In the absence of commercially available antimicrobial susceptibility tests, the CDC validated a new method for preparing broth microdilution (BMD) panels for aztreonam-avibactam antimicrobial susceptibility testing (AST) (11). Thereafter, the CDC deployed this test to four regional laboratories of the AR Lab Network to provide on-demand AST of aztreonam-avibactam for MBL-producing *Enterobacterales* (12). This study describes *in vitro* aztreonam-avibactam susceptibility of isolates tested from March 2019 to December 2020.
Enterobacterales isolates that met $\geq 1$ of the following criteria were eligible for aztreonam-avibactam AST at the AR Lab Network regional laboratories: (i) PCR-positive for $\geq 1$ MBL gene ($\text{bla}_{\text{IMP}}$, $\text{bla}_{\text{VIM}}$, or $\text{bla}_{\text{OXA-48-4bav}}$) or (ii) not susceptible to all beta-lactams tested by the submitting laboratory, including at least ceftazidime-avibactam and/or meropenem-vaborbactam.

The presence of carbapenemase genes was confirmed using CDC lab-developed real-time PCR methods or the GeneXpert Carba-R assay (Cepheid, Sunnyvale, CA). AST was performed in compliance with Clinical Laboratory Improvement Amendments guidelines for aztreonam, ceftazidime-avibactam, and aztreonam-avibactam using BMD panels prepared by the D300e digital dispenser (HP, Corvallis, OR) (11). The CDC provided laboratories with drug stock aliquots of aztreonam, ceftazidime, and avibactam and tubes containing 11 ml of cation-adjusted Mueller-Hinton broth. Quality control strains used were Escherichia coli (ATCC 25922), Pseudomonas aeruginosa (ATCC 27853), and Klebsiella pneumoniae (ATCC 700603). Participating laboratories also performed AST using Sensititre GNX2F BMD panels (Thermo Fisher Scientific, Waltham, MA) validated to have a final CFU/ml of approximately $5 \times 10^{5}$. Interpretive criteria were applied according to Clinical and Laboratory Standards Institute guidelines when available (13). Due to lack of interpretive criteria for aztreonam-avibactam, only an MIC was reported to submitters. Previous studies demonstrated that aztreonam-avibactam provided equivalent in vitro susceptibility for ceftazidime-avibactam plus aztreonam in highly resistant Enterobacterales; therefore, although patients receive ceftazidime-avibactam plus aztreonam, MICs for the triple combination were not reported (14). Results were typically reported to submitters within three working days.

Labs reported results to the CDC using a Research Electronic Data Capture (REDCap) database (Vanderbilt University, Nashville, TN). Results from one isolate per species per patient were included. If multiple isolates of the same species were submitted, the isolate with the earliest collection date was included. Data were analyzed using Statistical Analysis Software (v9.4; SAS Institute, Cary, NC).

Sixty-four isolates from 24 states submitted for aztreonam-avibactam AST met the inclusion criteria (Table S1). The organisms tested included Escherichia coli ($n = 28$), Klebsiella pneumoniae ($n = 24$), Enterobacter cloacae complex ($n = 10$), Morganella morganii ($n = 1$), and Proteus mirabilis ($n = 1$) (Table 1). Fifty-five isolates carried $\text{bla}_{\text{NDM}}$, eight harbored $\text{bla}_{\text{OXA-48-4bav}}$ and one harbored $\text{bla}_{\text{OXA-48}}$ genes. Specimen sources were urine ($n = 23$), blood ($n = 14$), respiratory ($n = 13$), rectal swabs ($n = 5$), and other ($n = 9$).

All isolates displayed resistance to ceftazidime-avibactam, and 93.8% (60/64) exhibited not susceptible MICs for aztreonam ($\geq 8 \mu g/ml$). Aztreonam-avibactam MICs ranged from 0.06/4 $\mu g/ml$ to 16/4 $\mu g/ml$, and the MIC$_{50}$ and MIC$_{90}$ were 0.5/4 $\mu g/ml$ and 8/4 $\mu g/ml$, respectively. For isolates not susceptible to aztreonam and ceftazidime-avibactam ($n = 60$), combining avibactam with aztreonam reduced the MIC of aztreonam by $\geq 4$-fold in all isolates, with a median reduction of $\geq 128$-fold. Moreover, the addition of avibactam restored susceptibility to aztreonam ($\leq 4 \mu g/ml$) in 85% (51/60) of these highly resistant isolates. In aztreonam-susceptible isolates ($n = 4$), avibactam had a negligible effect (no reduction or a 2-fold reduction) in three isolates with very low aztreonam MICs ($\leq 0.5 \mu g/ml$). For one isolate with reduced susceptibility to aztreonam alone (2 $\mu g/ml$), the presence of avibactam resulted in a 16-fold MIC reduction. Three NDM-producing isolates (2 $K$. pneumoniae and 1 $P$. mirabilis) were resistant to aztreonam and ceftazidime-avibactam and not susceptible to all other antimicrobials on the GNX2F panel (Table S2) but remained vulnerable to aztreonam-avibactam (0.06/4 to 1/4 $\mu g/ml$).

When examining MIC distributions by organism, $E$. coli demonstrated higher MIC$_{50}$ and MIC$_{90}$ results (4/4 $\mu g/ml$ and 8/4 $\mu g/ml$, respectively) than others (Table 1). A similar observation was made in a large study of 275 NDM-producing Enterobacteriales; the MIC$_{50}$ and MIC$_{90}$ were higher in 115 $E$. coli isolates (2/4 $\mu g/ml$ and 8/4 $\mu g/ml$, respectively) than the MIC$_{50}$ and MIC$_{90}$ observed in 125 $K$. pneumoniae isolates (0.25/4 $\mu g/ml$ and 0.5/4 $\mu g/ml$, respectively) (15). In our study, all 9 isolates for which avibactam did not restore aztreonam susceptibility were $E$. coli. This phenomenon could be explained by polymorphisms in the penicillin-binding protein 3 (16, 17); additional studies are needed to confirm their presence and role in our isolates.
One limitation of our study is the sample size—a small convenience sample of 64 highly resistant NDM-producing Enterobacterales. While our findings may not be generalizable to other organisms or other MBL carbapenemases circulating in Enterobacterales, this subset of isolates represents a rich collection of very rarely detected mechanisms, and the strict inclusion criteria employed for testing are consistent with the clinical and microbiological characteristics of infections for which aztreonam-avibactam (i.e., aztreonam and ceftazidime-avibactam) is an option for therapeutic consideration. Another limitation is that no patient outcome data were collected to ascertain whether aztreonam and ceftazidime-avibactam were subsequently coadministered for treatment and whether such treatment was effective. Finally, aztreonam-avibactam clinical breakpoints have not yet been established; therefore, the MIC data reported here must be interpreted cautiously.

In summary, organisms harboring MBLs confer resistance to many available antimicrobial agents and present clinicians with few, if any, effective treatment options. While our \textit{in vitro} data demonstrate that aztreonam-avibactam has considerable activity against \textit{Enterobacterales} coharboring MBL carbapenemases, specifically NDM, and certain other beta-lactamases capable of hydrolyzing aztreonam, more studies are necessary to assess the \textit{in vivo} efficacy of aztreonam-avibactam. As of 2021, all seven AR Lab Network regional laboratories now offer aztreonam-avibactam AST for MBL-producing \textit{Enterobacterales}, filling a critical gap by providing rapid results to help inform clinical treatment decisions (12).

### TABLE 1 MIC distributions for 64 Enterobacterales isolates tested against ceftazidime-avibactam, aztreonam, and aztreonam-avibactam: AR Lab Network, March 2019 to December 2020

| Isolate categories | Antimicrobial agent<sup>a</sup> | No. of isolates at each MIC (\(\mu g/ml\)) for each antimicrobial agent<sup>b</sup> | <0.03 | 0.06 | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | >64 | MIC<sub>50</sub><sup>c</sup> | MIC<sub>90</sub><sup>c</sup> |
|-------------------|--------------------------------|--------------------------------------------------------------------------------|-------|-----|-----|-----|-----|---|---|---|---|---|---|----|----|--------|--------|
| All (64)          | CZA                           | 64                                                                          |       |     |     |     |     | 41 | 4  | 8  |     |     |     |     | >64     | >64     |        |
|                   | ATM                           | 2                                                                           | 7     |     |     |     | 1   | 1  | 3  | 4  | 8  | 41 | 7  | 7  | 5.5 | 8       |        |
|                   | AZA                           | 14                                                                          | 11    | 13  | 7   | 1   | 9   | 2  | 7  | 4  | 8  | 3  | 1   |     | 8      |        |
| \textit{Escherichia coli} (28) | CZA                           | 28                                                                          |       |     |     |     |     |     | 2  | 3  | 3  |     |     |     |     | >64     | >64     |        |
|                   | ATM                           | 1                                                                           | 3     |     | 2   | 3   | 1   | 8  | 2  | 7  |     |     |     |     | 4       | 8       |        |
|                   | AZA                           | 1                                                                           | 4     |     | 3   | 2   | 1   | 8  | 2  | 7  |     |     |     |     | 4       | 8       |        |
| NDM (27)          | CZA                           | 27                                                                          |       |     |     |     |     |     | 2  | 3  | 3  | 18  |     |     | >64     | >64     |        |
|                   | ATM                           | 1                                                                           | 6     |     |     |     |     |     | 2  | 3  | 3  |     |     |     | 4       | 8       |        |
|                   | AZA                           | 1                                                                           | 4     |     | 3   | 2   | 1   | 8  | 2  | 7  |     |     |     | 4       | 8       |        |
| NDM & OXA-48-like (1) | CZA                           | 1                                                                           |       |     |     |     |     |     |     |     |     |     |     |     | 1      |        |        |
|                   | ATM                           | 1                                                                           |       |     |     |     |     |     |     |     |     |     |     |     | 1      |        |        |
|                   | AZA                           | 1                                                                           |       |     |     |     |     |     |     |     |     |     |     |     | 1      |        |        |
| \textit{Klebsiella pneumoniae} (24) | CZA                           | 24                                                                          |       |     |     |     |     |     |     |     |     |     |     |     | >64     | >64     |        |
|                   | ATM                           | 1                                                                           | 1     | 2   | 3   | 8   | 8   | 2   | 1  | 1  | 5  | 17  |     | >64     |        |        |
|                   | AZA                           | 3                                                                           | 1     | 2   | 8   | 8   | 2   | 1  |     |     | 1   | 7   |     | 0.25   | 1        |        |
| NDM (17)          | CZA                           | 17                                                                          |       |     |     |     |     |     |     |     |     |     |     |     | >64     | >64     |        |
|                   | ATM                           | 2                                                                           | 2     | 2   | 7   | 4   | 1   |     |     |     |     |     |     | 4       | 12      | >64     |
|                   | AZA                           | 2                                                                           | 2     | 2   | 7   | 4   | 1   |     |     |     |     |     |     | 0.25   | 1        | 4       |
| NDM & OXA-48-like (7) | CZA                           | 7                                                                           |       |     |     |     |     |     |     |     |     |     |     |     |        |        |        |
|                   | ATM                           | 1                                                                           | 1     | 1   | 4   |     |     |     |     |     |     |     |     | 1      |        |        |
|                   | AZA                           | 1                                                                           |       |     |     |     |     |     |     |     |     |     |     | 1      |        |        |
| \textit{Enterobacter cloacae} complex, NDM (10) | CZA                           | 10                                                                          |       |     |     |     |     |     |     |     |     |     |     |     | >64     | >64     |        |
|                   | ATM                           | 2                                                                           | 2     |     | 1   |     | 5   |     |     |     |     |     |     | 32     | >64     |        |
|                   | AZA                           | 2                                                                           | 1     |     | 3   | 1   |     |     |     |     |     |     | 0.25   | 1        | 4       |
| \textit{Morganella morganii}, NDM & KPC (1) | CZA                           | 1                                                                           |       |     |     |     |     |     |     |     |     |     |     |     |        |        |        |
|                   | ATM                           | 1                                                                           |       |     |     |     |     |     |     |     |     |     |     | 1      |        |        |
|                   | AZA                           | 1                                                                           |       |     |     |     |     |     |     |     |     |     |     | 1      |        |        |
| \textit{Proteus mirabilis}, NDM (1)   | CZA                           | 1                                                                           |       |     |     |     |     |     |     |     |     |     |     |     |        |        |        |
|                   | ATM                           | 1                                                                           |       |     |     |     |     |     |     |     |     |     |     | 1      |        |        |
|                   | AZA                           | 1                                                                           |       |     |     |     |     |     |     |     |     |     |     | 1      |        |        |

\footnotesize<a>ATM, aztreonam; AZA, aztreonam-avibactam; CZA, ceftazidime-avibactam. Avibactam is at a constant concentration of 4 \(\mu g/ml\) when in combination.</a>

\footnotesize<b>Gray shading indicates the not susceptible ranges for CZA and ATM. AZA does not have interpretive criteria.</b>

\footnotesize<c>MIC<sub>50</sub> and MIC<sub>90</sub> were calculated only for groups with \(>9\) isolates.</c>
Interested health care and public health professionals can contact their AR Lab Network regional laboratory for more information.

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

SUPPLEMENTAL FILE 1, PDF file, 0.04 MB.
SUPPLEMENTAL FILE 2, XLSX file, 0.01 MB.

ACKNOWLEDGMENTS

The findings and conclusions in this report are those of the author(s) and do not represent the official position of the Centers for Disease Control and Prevention. This work was supported by the Centers for Disease Control and Prevention’s internal funding.

REFERENCES

1. Centers for Disease Control and Prevention. 2019. Antibiotic resistance threats in the United States, 2019. U.S. Department of Health and Human Services, CDC, Atlanta, GA.
2. Centers for Disease Control and Prevention. 2020. Antimicrobial Resistance & Patient Safety Portal (AR&PSP) AR Lab Network data. CDC, U.S. Department of Health and Human Services, Atlanta, GA. https://arpsp.cdc.gov/.
3. Meletis G. 2016. Carbapenem resistance: overview of the problem and future perspectives. Ther Adv Infect Dis 3:13–21. https://doi.org/10.1177/2049936115621709.
4. Shaw E, Rombauts A, Tubau F, Padullés A, Cámara J, Lozano T, Cobos-Sacrístán S, Sabe N, Grau I, Rigo-Bonnin R, Domínguez MA, Carratalà J. 2018. Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM–1/OXA–48/CTX–M–15-producing Klebsiella pneumoniae infection. J Antimicrob Chemother 73:1104–1106. https://doi.org/10.1093/jac/dkx496.
5. Marshall S, Hujer AM, Rojas LJ, Papp-Wallace KM, Spellberg B, Hujer KM, Marshall EK, Rudin SD, Perez F, Wilson BM, Wessman RB, Chikowsky L, Paterson DL, Vila AJ, van Duijn D, Kreiswirth BN, Chambers HF, Fowler VG, Jr, Jacobs MR, Pulse ME, Weiss WJ, Bonomo RA. 2017. Can ceftazi-dime-avibactam and aztreonam overcome beta-lactam resistance conferred by metallo-beta-lactamas in Enterobacteriaceae? Antimicrob Agents Chemother 61:e02243-16. https://doi.org/10.1128/AAC.02243-16.
6. Sader HS, Mendes RE, Pfaffer MA, Shortridge D, Flamm RK, Castanheira M. 2017. Antimicrobial activities of aztreonam-avibactam and comparator agents against contemporary (2016) Enterobacteriaceae isolates. Antimicrob Agents Chemother 62:e01856-17. https://doi.org/10.1128/AAC.01856-17.
7. Vasoo S, Cunningham SA, Cole NC, Kohner PC, Menon SR, Krause KM, Harris KA, De PP, Koh TH, Patel R. 2015. In vitro activities of ceftazidime-avibactam, aztreonam-avibactam, and a panel of older and contemporary antimicrobial agents against carbapenemase-producing Gram-negative Bacilli. Antimicrob Agents Chemother 59:7842–7846. https://doi.org/10.1128/AAC.02019-15.
8. Karlowsky JA, Kazmierczak KM, de Jonge BLM, Hackel MA, Sahm DF, Bradford PA. 2017. In vitro activity of aztreonam-avibactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated by clinical laboratories in 40 countries from 2012 to 2015. Antimicrob Agents Chemother 61: e00472-17. https://doi.org/10.1128/AAC.00472-17.
9. Biedenbach DJ, Kazmierczak K, Bouchillon SK, Sahm DF, Bradford PA. 2015. In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013. Antimicrob Agents Chemother 59:4239–4248. https://doi.org/10.1128/AAC.02066-15.
10. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duijn D, Clancy CJ. 2020. Infectious Diseases Society of America guidance on the treatment of extended-spectrum beta-lactamase producing Enterobacteriales (ESBL-E), carbapenem-resistant Enterobacteriales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis https://doi.org/10.1093/cid/ciaa1478.
11. Ransom E, Bhatnagar A, Patel JB, Machado M, Boyd S, Reese N, Lutgring JD, Lonswy D, Anderson K, Brown AC, Elkins CA, Rasheed JK, Karlsson M. 2020. Validation of aztreonam-avibactam susceptibility testing using digitally dispensed custom panels. J Clin Microbiol 58:e01944-19. https://doi.org/10.1128/JCM.01944-19.
12. Centers for Disease Control and Prevention. 2019. Expanded antimicrobial susceptibility testing for hard-to-treat infections (ExAST). Centers for Disease Control and Prevention. https://www.cdc.gov/drugresistance/laboratories/ar-lab-network-testing-details/expanded-ast.html. Accessed 31 October 2020.
13. Clinical and Laboratory Standards Institute. 2020. Performance standards for antimicrobial susceptibility testing. CLSI document M100, 30th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
14. Bhatnagar A, Ransom EM, Machado M, Boyd S, Reese N, Anderson K, Lonswy D, Elkins CA, Rasheed JK, Karlsson M, Brown AC, Lutgring JD. 2021. Assessing the in vitro impact of ceftazidime on aztreonam/avibactam susceptibility testing for highly resistant MBL-producing Enterobacteriales. J Antimicrob Chemother 67:979–983. https://doi.org/10.1093/jac/dkaa531.
15. Lutgring JD, Balbuena R, Reese N, Gilbert SE, Ansari U, Bhatnagar A, Boyd S, Campbell D, Cochran J, Haynie J, Ilutiskj J, Longo C, Swint S, Rasheed JK, Brown AC, Karlsson M. 2020. Antibiotic susceptibility of NDM-producing Enterobacteriales collected in the United States, 2017–2018. Antimicrob Agents Chemother 64:e00499-20. https://doi.org/10.1128/AAC.00499-20.
16. Zhang Y, Kashikar A, Brown CA, Denys G, Bush K. 2017. Unusual Escherichia coli PBP 3 insertion sequence identified from a collection of carbapenem-resistant Enterobacteriaceae tested in vitro with a combination of ceftazidime-, ceftaroline-, or aztreonam-avibactam. Antimicrob Agents Chemother 61:e00389-17. https://doi.org/10.1128/AAC.00389-17.
17. Alm RA, Johnstone MR, Lahiri SD. 2015. Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP8. J Antimicrob Chemother 70:1420–1428. https://doi.org/10.1093/jac/dku568.